Clinical trial NCT05136937: A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors
Official title: An Open-Label, Dose Escalation Study of the Safety and Tolerability of Oncolytic Virus Injection(RT-01) When Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Solid Tumor
Advanced Cancer
Keywords: RT-01
immunotherapy
intratumoral injection
oncolytic virus
Lead sponsor: Wuxi People's Hospital
Sponsor class: OTHER
First posted: 2021-11-30
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: Administered by intratumoral injection for 3 dose cohorts: 1×10\^7 TCID50/mL, 1×10\^8 TCID50/mL and 5×10\^8 TCID50/mL
Primary purpose: TREATMENT

Brief summary: This is an open-label, dose escalation study of the safety and tolerability of oncolytic virus injection(RT-01) when administered via intratumoral injection in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of RT-01 and to determine the recommended phase 2 dose (RP2D) for further study. The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of RT-01.

Detailed description: This is an investigator initiated , open-label, study of RT-01 given via intratumoral (IT) injection as a single agent in participants with advanced solid tumors. The study is a single agent dose escalation which will use a 3+3 design to evaluate escalating doses of RT-01. Total enrollment will depend on the toxicities and/or activity observed, with approximately 7-18 evaluable participants enrolled.

The primary study objective is to determine the safety, tolerability, and maximum tolerated dose (MTD) of intratumoral administration of RT-01 as a single agent. Secondary objectives will assess efficacy overall response rate, as well as disease control rate, progression free survival, duration of response, and anti-tumor immune responses.

Eligibility criteria: Inclusion Criteria:

* Male or female aged ≥ 18 years;
* Subjects must have histologically- or cytologically-confirmed diagnosis of advanced solid tumor(s) and have progressed on or is not eligible for available standard therapy;
* Subjects have At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (non-nodal lesions with longest diameter ≥ 10 mm, or nodal lesions with short diameter ≥ 15 mm);
* ECOG score of 0 \~ 2;
* Adequate bone marrow, hepatic and renal and coagulation function;
* Women of childbearing age who have a negative pregnancy test within 7 days before treatment. Female patients of childbearing age, and male patients with partners of childbearing age must agree to use at least one medically recognized contraceptive method during study treatment and within at least 6 months after the last dose of investigational drug;
* Voluntarily participated in this study, signed the informed consent form, had good compliance, and cooperated with the follow-up.

Exclusion Criteria:

* Subjects with known brain metastasis and/or clinically history tumor brain of metastasis；
* Subjects who have received anti-tumor therapy such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, etc within 4 weeks；
* Subjects who have participate in another interventional study while receiving study IP within 4 weeks；
* Subjects who have had major surgery ≤ 4 weeks of dosing；
* Patients in any condition requiring systemic treatment with corticosteroids (prednisone \> 10 mg/day or equivalent of the similar drug) or other immunosuppressive agents within 14 days prior to investigational drug administration, but currently or previously treated with any of the following steroid regimens, were included:

  * Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption;
  * Prophylactic short-term (≤ 7 days) use of corticosteroids (e.g., allergy to contrast media) or for the treatment of non-autoimmune diseases (e.g., delayed hypersensitivity caused by contact allergens)
* Subjects received live vaccines within 7 days of initiation of study treatment；
* Subjects with adverse reactions caused by previous anti-tumor treatment not recovered to (CTCAE 5.0) grade 1 (except alopecia)；
* Subjects who have any active infection；
* Subjects with known positive history of human immunodeficiency virus (HIV) test or known acquired immunodeficiency syndrome (AIDS)；
* Subjects who have active hepatitis；
* Subjects who have serious cardiovascular system disorders history；
* Subjects with active autoimmune diseases or history of autoimmune diseases that may relapse；
* Subjects having any serious uncontrolled disease or in other conditions that would preclude them from receiving study treatment and are considered unsuitable for this study in the opinion of the investigator.
* Subjects in other conditions that are considered unsuitable for this study by the investigator.

Primary outcomes:
measure: Dose Limiting Toxicities (DLT)
timeFrame: Up to 28 days
Secondary outcomes:
measure: Safety and tolerability assessed by Adverse Events (AEs)
timeFrame: Up to 6 months
measure: Number of participants with laboratory value abnormalities and/or adverse events
timeFrame: Up to 6 months
measure: Number of participants with vital sign abnormalities and /or adverse event
timeFrame: Up to 6 months
measure: Safety assessed by 12- lead electrocardiograms (ECGs) adverse events
timeFrame: Up to 6 months
measure: To evaluate the efficacy assessed per RECIST and iRECIST
timeFrame: Up to 2 years form first dose of RT-01
measure: Number of Participants With Response
timeFrame: at baseline, 2, 4, 7, 14, 28 days after injection
measure: Viral shedding of RT-01 in blood
timeFrame: Up to 6 months
measure: Presence of neutralizing antibodies of antidrug antibodies (ADAs) development
timeFrame: Up to 6 months
Other outcomes:
Locations:
city: Wuxi
country: China
facility: Wuxi People's Hospital
state: Jiangsu
Study officials:
References: